89Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer

First-in-human study of 89Zr-pembrolizumab PET/CT in patients with advanced stage non-small-cell lung cancer

(2021) Anna-Larissa Nadia Niemeijer et al.   JOURNAL OF NUCLEAR MEDICINE

The Role of PD-1 in Acute and Chronic Infection

(2020) Jil M. Jubel et al.   Frontiers in Immunology

PET/CT Imaging of 89Zr-N-sucDf-Pembrolizumab in Healthy Cynomolgus Monkeys

(2020) Wenping Li et al.   MOLECULAR IMAGING AND BIOLOGY

89Zr-pembrolizumab biodistribution is influenced by PD-1-mediated uptake in lymphoid organs

(2020) Elly L van der Veen et al.   Journal for ImmunoTherapy of Cancer

Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response

(2019) Alexander Haragan et al.   LUNG CANCER

Multiomics Prediction of Response Rates to Therapies to Inhibit Programmed Cell Death 1 and Programmed Cell Death 1 Ligand 1

(2019) Joo Sang Lee et al.   JAMA Oncology

Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC

(2018) MARIA BASSANELLI et al.   ANTICANCER RESEARCH

Comparative biodistribution analysis across four different 89Zr-monoclonal antibody tracers—The first step towards an imaging warehouse

(2018) Frederike Bensch et al.   Theranostics

89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer

(2018) Frederike Bensch et al.   NATURE MEDICINE

Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer

(2018) A. N. Niemeijer et al.   Nature Communications

Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis

(2018) Cheng Xu et al.   BMJ-British Medical Journal

PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data

(2017) Pedro N Aguiar et al.   Immunotherapy

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

(2017) Achim Rittmeyer et al.   LANCET

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

(2017) Lesley Seymour et al.   LANCET ONCOLOGY

A molecular and preclinical comparison of the PD-1–targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab

(2017) Petros Fessas et al.   SEMINARS IN ONCOLOGY

Development of a Companion Diagnostic for Pembrolizumab in Non–Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1

(2016) Marisa Dolled-Filhart et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma

(2016) J. Madore et al.   CLINICAL CANCER RESEARCH

Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway

(2016) Vassiliki A. Boussiotis   NEW ENGLAND JOURNAL OF MEDICINE

Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

(2015) A. Patnaik et al.   CLINICAL CANCER RESEARCH

PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials

(2014) Jason Madore et al.   Pigment Cell & Melanoma Research

Repeatability of Metabolically Active Tumor Volume Measurements with FDG PET/CT in Advanced Gastrointestinal Malignancies: A Multicenter Study

(2014) Virginie Frings et al.   RADIOLOGY

Multicenter Harmonization of 89Zr PET/CT Performance

(2013) N. E. Makris et al.   JOURNAL OF NUCLEAR MEDICINE

A Partial Volume Effect Correction Tailored for18F-FDG-PET Oncological Studies

(2013) F. Gallivanone et al.   Biomed Research International